Navigation
banner

ImmunoTX Summit

2018-02-182017-12-312017-10-31
Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Erika Brown

Erika Brown
President & Chief Executive Officer (And NED patient 15 years, Co-Founder for the TOM'S TRIALS Patient/Caregiver Groups in COLONTOWN)
PALTOWN Development Foundation
Erika Brown
President & Chief Executive Officer (And NED patient 15 years, Co-Founder for the TOM'S TRIALS Patient/Caregiver Groups in COLONTOWN)
PALTOWN Development Foundation
 
About Speaker:

Ms. Brown, a Montana native, had a healthy career as a corporate executive search professional until - at age 58 - she was diagnosed with late-stage colorectal cancer.  Treatment completed, her interests refocused upon the undeveloped niche of disease-specific patient empowerment.

Patient Power has taken a step forward with her founding of PALTOWN Development Foundation.  PALTOWN supports its first community - COLONTOWN, “where experience reaches out.” It is an  online community made up of deeply engaged, “wildly supportive”, experience-specific, secret support groups that are exclusively dedicated to CRC patients and family members.  COLONTOWN has become a model for patient community-building, creating a template for successful community for patients of other disease states to follow.

Brown is grateful, empowered, and disease-free - 15 years later.

Scott Durum

Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
 
About Speaker:

Scott Durum trained in immunology at Wake Forest, Oak Ridge, National Jewish and Yale before coming to the National Cancer Institute, National Institutes of Health. His lab has been interested in the IL-7 pathway for a number of years. Recently, together with collaborators, they found that this is a major pathway driving Acute Lymphoblastic Leukemia, the most common cancer in children. They are working to develop therapeutics directed against the IL-7 pathway in this disease.

Gordon Freeman

Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
 
About Speaker:

Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School.  Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University.  His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).

In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction.  He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack.  He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and 2017 Warren Alpert Foundation award for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.

Michael Karin

Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
 
About Speaker:

Dr. Karin was born in Tel Aviv, Israel and received the Bachelor of Science degree in 1975 from Tel Aviv University, with a major in Biology. In 1975 he arrived in the US and in 1979 received a Ph.D. degree in Molecular Biology from the University of California, Los Angeles. Dr. Karin followed his graduate studies with postdoctoral fellowships at the Fox Chase Institute for Cancer Research, working in the laboratory of Dr. Beatrice Mintz, and the laboratory of Dr. John Baxter at the University of California, San Francisco. Dr. Karin joined the faculty at the University of California, San Diego in 1986, where currently he is a Distinguished Professor of Pharmacology.

Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society in 1990, an American Cancer Society Research Professorship in 1999, the C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin in 2000, the Harvey Prize in Human Health in 2011, the Brupbacher Prize in Cancer Research in 2013 and the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology in 2013. Dr. Karin was elected to the National Academy of Sciences in 2005, as a Foreign Associate of EMBO in 2007, and to the Institute of Medicine in 2011. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).

Andrew Vandergrift

Andrew Vandergrift
Patient Advocacy Liaison
Ignyta
Andrew Vandergrift
Patient Advocacy Liaison
Ignyta
 
About Speaker:
PLENARY SPEAKERS
Kevin Murray

Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
 
About Speaker:

Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.

Cytokines & Inflammation
DISTINGUISHED SPEAKERS
Rachel Caspi

Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
 
About Speaker:

Dr. Caspi is is a tenured senior investigator, Section Head and Chief of the Laboratory of Immunology, National Eye Institute, NIH. She also holds an Adjunct Professorship at the University of Pennsylvannia Sch. Med. Dr. Caspi's research centers on immunology of the eye. A major direction is tolerance and autoimmunity to immunologically privileged retinal antigens in animal models of autoimmune uveitis, a potentially blinding human disease. She developed the mouse model of autoimmune uveitis, now in use worldwide. Her studies have elucidated many basic mechanisms of pathogenesis and helped to devise clinically relevant immunotherapeutic approaches. Her recent work emphasizes the Th17 response and the effects of the commensal microbiome on anti-retinal autoimmunity as well as on mucosal immunity and host defense at the ocular surface. She serves on journal Editorial Boards and is an organizer of ocular and general immunology conferences. Dr. Caspi is the recipient of the highly prestigious Friedenwald award and the Alcon Research Institute award, and has authored and co-authored over 240 publications.

Manoj Dadlani

Manoj Dadlani
Chief Executive Officer
CosmosID
Manoj Dadlani
Chief Executive Officer
CosmosID
 
About Speaker:

Mr. Manoj Dadlani serves as Chief Executive Officer at CosmosID, Inc., a genomic big data company focused on rapid identification of microorganisms for infectious disease diagnostics, public health surveillance, food safety monitoring, pharmaceutical discovery, and microbiome analysis for health and wellness. Previously, Mr. Dadlani served as a partner at Applied Value Group, a management consulting and investment firm, and was co-founder and Chief Executive Officer at Rasa Industries, Ltd., a leading beverage manufacturing company in northern Nigeria. Mr. Dadlani has substantial experience in strategy, M&A, supply chain management, product development, marketing and business development. At Applied Value, he lead the US business in management consulting, advising fortune 500 companies in both revenue growth, cost reduction and lean management. As his role as CEO of CosmosID, Mr. Dadlani has lead the company to commercialize current products and develop new products in the microbial identification and characterization space. Mr. Dadlani received his Bachelors and Masters degrees in Biological Engineering from Cornell University.

John Eid

John Eid
Chief Scientific Officer and Co-Founder
Whole Biome
John Eid
Chief Scientific Officer and Co-Founder
Whole Biome
 
About Speaker:

John Eid is the CSO and Co-Founder of Whole Biome Inc. He has led fundamental technology development for over a decade in diverse areas that include advanced microscopy, single molecule detection and analyses, automated data acquisition systems, biophysical system modeling, and genome sequencing applications. Prior to co-founding Whole Biome, he was a Principal Scientist at Pacific Biosciences. He completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.

Ling-Yang Hao

Ling-Yang Hao
Principal Scientist, Immunology Biomarkers
Janssen R&D
Ling-Yang Hao
Principal Scientist, Immunology Biomarkers
Janssen R&D
 
About Speaker:

Ling-Yang is currently a Principal Scientist at Janssen R&D within Johnson & Johnson Pharmaceutical sector. His role focuses on providing biomarkers support for inflammatory bowel disease (IBD) assets within Immunology Therapeutic Area. Ling-Yang has been working on biomarkers with Janssen R&D since 2015. Prior to joining Janssen R&D, Ling-Yang worked on target discovery around T lymphocyte metabolic space at Lycera Corp. Earlier in his career, Ling-Yang received his Ph.D. at the Johns Hopkins School of Medicine studying telomere biology and DNA damage responses and trained as a post doctoral researcher at the University of Pennsylvania and Howard Hughes Medical Institute on mechanisms of neurodegeneration.

Michael Howell

Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
 
About Speaker:

Michael Howell currently works as the Senior Director of Translational Research at the Incyte Corporation with a focus on immunological diseases. Dr. Howell received his PhD in Immunology from the West Virginia University School of Medicine and then moved onto National Jewish Medical and Research Center where he transitioned from a post doctoral fellow to Assistant Professor in the Division of Allergy and Immunology. While at NJMRC, he served as a Co-Investigator for the Atopic Dermatitis Vaccinia Network and made seminal discoveries in the role of Th2 cytokines on the barrier and innate immune responses of atopic dermatitis patients. Since transitioning to industry, Dr. Howell has held positions at Boehringer Ingelheim, the Immune Tolerance Network, MedImmune, and Incyte. Throughout his career, Dr. Howell has combined clinical and basic science approaches to evaluate inflammatory diseases. This research has been highlighted in national and international meetings, peer-reviewed publications and reviews on immunologic mechanisms and has led to recent patent applications for therapeutic interventions and biomarker strategies in inflammatory diseases.

Xiao Hu

Xiao Hu
Executive Director
Lycera Corp
Xiao Hu
Executive Director
Lycera Corp
 
About Speaker:

Dr. Xiao Hu is currently Executive Director of Biology, head of the immune oncology group at Lycera Corp. He joined Lycera in 2010 bringing extensive experience in drug discovery, particularly around nuclear receptors, metabolic enzymes and gene regulation. Prior to Lycera Dr. Hu was a group and project leader at Pfizer/Pharmacia, where in 10 years he initiated and led multiple projects from idea to clinical testing, resulting in 4 successful IND filings and Phase I trials in inflammation/autoimmune/metabolic diseases. Since joining Lycera, Dr. Hu has held key leadership roles in projects targeting RORgamma for immunotherapy of cancer and for autoimmune diseases. He contributed significantly to the successful completion of Phase I and initiation of II trials of a RORgamma agonist compound in cancer patients. He has also been responsible for initiating and executing multiple new projects targeting novel immune oncology mechanisms.

Dr. Hu is an active member of SITC (Society for Immunotherapy of Cancer) and Endocrine Society. He received his B.S. from University of Science and Technology of China, Ph.D. from Indiana University and completed his postdoctoral training on transcriptional regulation of metabolism at University of Pennsylvania with Dr. Mitchell Lazar.

Alison Humbles

Alison Humbles
Principal Scientist
MedImmune
Alison Humbles
Principal Scientist
MedImmune
 
About Speaker:
Ignacio Juncadella

Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
 
About Speaker:

Ignacio J. Juncadella currently works as a principal scientist and project leader in the department of Immunology and Respiratory Disease Research at Boehhringer Ingelheim, Inc. His research primarily focuses on the identification and validation of therapeutic concepts related to inflammation, autoimmunity and fibrotic pathways in human disease. Ignacio obtained his Ph.D. from the University of Massachusetts Amherst in 2008. Ignacio joined Boehringer Ingelheim after his postdoctoral training with Dr. Kodi S. Ravichandran at the University of Virginia where he studied mechanisms of tissue tolerance and homeostasis, innate immunity and how defects in apoptotic cell clearance, a process call ‘efferocytosis’ results in exacerbated lung inflammation.

Dermot McGovern

Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA School of Medicine
Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA School of Medicine
 
About Speaker:

Dermot McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford before moving to Cedars-Sinai, Los Angeles almost 10 years ago. Dr McGovern’s clinical practice is in a tertiary referral center for complex IBD. Dr McGovern serves on the National Scientific Advisory Committee for the Crohn’s and Colitis Foundation of America as well as the steering committees of the National and International IBD Genetics Consortia. He also chairs the CCFA local advisory medical committee. His group is funded by the NIH to study the effect of genetics on the susceptibility to and natural history of IBD in diverse populations. Dr McGovern’s group analyze multi’-omic’ datasets to identify potential therapeutic targets of IBD that ‘feed’ the Drug Development Unit he co-directs. He is a member of the American Society for Clinical Investigation and also the International Organization for the Study of IBD (IOIBD). Dr McGovern has recently been appointed the Director of the Cedars-Sinai Precision Medicine Initiative.

Kingston HG Mills

Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
 
About Speaker:

Kingston Mills is Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin (TCD). He is Head of the Immunology, Inflammation and Infection research theme at TCD and Head of the Centre for the Study of Immunology in TBSI. He trained at as a Postdoctoral Fellow at University College London and the MRC National Institute for Medical Research, Mill Hill, London (now the Crick Institute), before joining the Scientific Staff of National Institute for Biological Standards and Control (NIBSC), Herts, UK. He was appointed to a Personal Chair at TCD in 2001 and was Head of the School of Biochemistry and Immunology from 2008-2011. He is a co-founder of University spin-out companies Opsona Therapeutics and TriMod Therapeutics. His research focuses on the role of the immune system, in particular T cell subtypes, in immunity to infection, cancer and autoimmunity.

Laurence Morel

Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
 
About Speaker:

Laurence Morel obtained her PhD from the University of Aix-Marseille (France). She trained as a postdoctoral fellow with Dr. Ward Wakeland at the University of Florida (USA) in immunogenetics, where she started to work on the genetic basis of lupus in mouse models. She was appointed with a faculty position in the department of Pathology, Immunology, and Laboratory Medicine at UF in 1999, where she is currently a tenured professor and the Vice Chair for Research and Academic Affairs. Her research focuses on the mechanisms of lupus pathogenesis using mouse models as well as patients’ samples. In addition to genetic studies, her studies now extend to immune metabolism, the role of the microbiome, and the contribution of mesenchymal stem cells to lupus pathogenesis. Her long-term goal is to identify genes and pathways responsible for lupus susceptibility, to characterize their contribution to autoimmune immunopathology, and to translate these findings into therapeutic targets.

Cathryn Nagler

Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
 
About Speaker:

Cathryn Nagler graduated with honors from Barnard College, Columbia University. She obtained her Ph.D. from the Sackler Institute of Biomedical Science at N.Y.U. School of Medicine and did a postdoctoral fellowship at M.I.T. She was Associate Professor of Pediatrics (Immunology) at Harvard Medical School prior to joining the University of Chicago in 2009. She received the inaugural Bunning Food Allergy Professorship in 2011. Dr. Nagler has participated in numerous review panels for the Crohn’s and Colitis Foundation of America, NIDDK, NIAID, and Food Allergy Research and Education (FARE). She recently began her second term on FARE’s research advisory board. She has served the American Association of Immunologists (AAI) as Section Editor for the Journal of Immunology, Instructor (Mucosal Immunology) for the Introduction to Immunology course and as member of the Program, Clinical Immunology, Publications and Awards Committees. She is the senior editor for Clinical and Translational Immunology for the AAI’s new journal ImmunoHorizons. She has also served as an elected Councilor of the Society for Mucosal Immunology and is an Associate Editor of the journal Mucosal Immunology. Dr. Nagler has a long-standing interest in the mechanisms governing tolerance to dietary antigens and the potential immunomodulatory features of the oral route of antigen administration. Her most recent work examines how commensal bacteria regulate susceptibility to allergic responses to food. She has applied insights gained from studying pre-clinical gnotobiotic murine models of cow’s milk allergy to launch a new company, ClostraBio, which is developing microbiome-modulating therapeutics for the prevention and treatment of food allergy.

Stanley Perlman

Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
 
About Speaker:

Dr. Perlman currently investigates the pathogenesis of coronavirus-mediated severe human respiratory disease (severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) and of coronavirus-induced demyelination. His laboratory also has a strong interest in the regulatory T cells in the context of infection. He has developed severe animal models for the study of MERS and has also investigated T cell responses in MERS survivors. Prior to joining the faculty of the University of Iowa in 1983, he obtained his Ph.D. at M.I.T. and his M.D. at the University of Miami.

Thomas Schall

Thomas Schall
President and Chief Executive Officer
ChemoCentryx
Thomas Schall
President and Chief Executive Officer
ChemoCentryx
 
About Speaker:

Dr. Schall is the founder of ChemoCentryx, Inc. and has served as the President, Chief Executive Officer and Director since the company commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Pejman Soroosh

Pejman Soroosh
Principal Scientist and Head, Immunobiology Research Team (IRT)
Janssen
Pejman Soroosh
Principal Scientist and Head, Immunobiology Research Team (IRT)
Janssen
 
About Speaker:

Pejman Soroosh is a Principal Scientist at Janssen Research and Development, San Diego. He received his Ph.D. in 2008 from Tohoku University, Japan. He performed postdoctoral work at La Jolla Institute for Allergy and Immunology (LIAI) where he investigated the mechanism by which co-stimulatory molecules on T cells contribute to dysregulation of airway tolerance and development of asthma. In 2010 he joined the Immunology Department at Janssen R&D where he was involved in the drug discovery efforts as a project leader and responsible for direct scientific management of internal and external projects. In 2014 he co-founded Immunology Exploratory Science Lab (I-ExSL) within Immunology department to study innate immune responses at mucosal tissues. In 2016 he created Immunobiology Research Team (IRT) within Janssen R&D with a goal to identify unique immune metabolism targets influencing T cell/APC biology & determine pharmacologic tractability to promote immune tolerance for autoimmunity.

Howard Spiegel

Howard Spiegel
Simple Plex Specialist
Protein Simple, A Division of Bio-Techne
Howard Spiegel
Simple Plex Specialist
Protein Simple, A Division of Bio-Techne
 
About Speaker:

Howard Spiegel is a reformed bench scientist. He earned his technical skills working under Tony Fauci (when he was a merely a Section Head) making and purifying synthetic peptides. After scoring too low on MCAT and GRE he sold his soul and became a salesman. For the last 30 years Howard has found a way to maintain integrity while serving the research community. Howard joined MesoScale(MSD) in the early days of 2004 and then ProteinSimple (that became Bio-Techne) in 2014. He now takes his work wife (ELLA) on the road and wows scientist with hands-free 90-minute ELISA’s.

Immunotherapeutics & Immunomonitoring
DISTINGUISHED SPEAKERS
Brian Champion

Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
 
About Speaker:

Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, tumor-specific immunogene therapies for the treatment of cancer.   He was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California, leading the immunology team providing expertise and immunoassays for Pfizer vaccine projects, program leader for an anti-IgE therapeutic vaccine for allergy/asthma, and a member of the leadership team. Prior to this he was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex in Cambridge (UK) developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.

Preet Chaudhary

Preet Chaudhary
Chief of Jane Anne Nohl Division of Hematology and Center for Study of Blood Diseases, Director of Blood and Marrow Transplant Program
University of Southern California, Los Angeles
Preet Chaudhary
Chief of Jane Anne Nohl Division of Hematology and Center for Study of Blood Diseases, Director of Blood and Marrow Transplant Program
University of Southern California, Los Angeles
 
About Speaker:

Preet M. Chaudhary, M.D., Ph.D. is chief of the Jane Anne Nohl Division of Hematology and Center for the study of Blood Diseases in the Department of Medicine, and coleader of the Molecular Genetics Program at the USC Norris Comprehensive Cancer Center. He is also Professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and Program Director of the USC/Norris Blood and Marrow Transplant Program. Current research work in Dr. Chaudhary's laboratory is focused on chimeric antigen receptor modified T cells for the treatment of cancer.

Deborah Goldberg

Deborah Goldberg
Patient
Stage IV Colorectal Cancer Patient
Deborah Goldberg
Patient
Stage IV Colorectal Cancer Patient
 
About Speaker:

Deborah Goldberg grew up in Portland, Oregon where she met her childhood sweetheart, a German exchange student. They have been married for 22 years and have 3 amazing children. She received a BA from Brown University and a JD from UCLA. She practiced law for many years. Then, after loosing her beloved mother and mother-in-law to cancer, she was diagnosed with Stage IV cancer and has been a patient at the Stanford Cancer Center since 2014.

Michael Gresser

Michael Gresser
Chief Scientific Officer
Immungene
Michael Gresser
Chief Scientific Officer
Immungene
 
About Speaker:

Mike Gresser, Ph.D. is Chief Scientific Officer for ImmuneGene. From 2000-2006, Dr. Gresser served as Vice President, Research for Inflammation at Amgen, Inc. Prior to Amgen, he was at the Merck Frosst Center for Therapeutic Research where he rose to be Executive Director of Biochemistry and Molecular Biology. He received his Ph.D in Biochemistry from Brandeis University and did postdoctoral studies at UCLA. Before joining Merck Frosst in 1988 he was Pr ofessor of Chemistry at Simon Frazer University in Burnaby, British Columbia.

Ulrich Hoffmueller

Ulrich Hoffmueller
Vice President, Immune Monitoring Solutions
Epiontis, Precision for Medicine
Ulrich Hoffmueller
Vice President, Immune Monitoring Solutions
Epiontis, Precision for Medicine
 
About Speaker:

Since the foundation of Epiontis in 2003, in which Uli participated as a founder, he is Chief Business Officer of the company. Prior to founding Epiontis, he worked at Jerini AG, Berlin, Germany (now part of Shire Pharmaceuticals) from 1999 to 2003 as Director of Business Development. Uli completed business school in Berlin, Germany and Cambridge, UK from 2002 to 2004 in parallel to his positions in the biotech industry. He earned his Ph.D. at the Charité University Clinic, Berlin, Germany, in 1998, and was honored with the Charité Research Award in 1997. Uli received his Diplom (Masters) in Biochemistry in 1995 from Humboldt University, Berlin, Germany.

Karin Jooss

Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone Oncology
Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone Oncology
 
About Speaker: Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology. Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years. While at Pfizer, she built and led immuno-oncology teams, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunopharmacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and developing and launching Pfizer’s first clinical cancer vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Jooss served as vice president of Research at Cell Genesys, Inc. where she oversaw all research activities related to the company’s cancer vaccine and oncolytic virotherapy programs. Dr.Jooss received her Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania. She is on the editorial board of Molecular Therapy and Journal of Gene Medicine and is a member of the immunology and educational committee for the American Society of Gene Therapy as well as the Industry Task Force of the Society for Immunotherapy of Cancer (SITC).
Holly Koblish

Holly Koblish
Director, Pharmacology
Incyte Research Institute
Holly Koblish
Director, Pharmacology
Incyte Research Institute
 
About Speaker:

Holly received her Ph.D. in Molecular and Cell Biology from the University of Pennsylvania and completed her postdoctoral training at Princeton University. Prior to joining Incyte in 2006, Holly held scientific research positions with 3-Dimensional Pharmaceuticals and Johnson and Johnson. At Incyte, Holly has been involved in target validation and drug discovery efforts within oncology. She has been involved with a number of Incyte’s kinase programs, including PIM, FGFR and c-Met, and immuno-oncology programs including IDO1, arginase, GITR and OX40.

Sean Mackay

Sean Mackay
CEO
IsoPlexis
Sean Mackay
CEO
IsoPlexis
 
About Speaker:

Sean is the CEO of Isoplexis. IsoPlexis is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. IsoPlexis has created a next-generation system, capable of identifying and predicting patient responses to immunotherapy more accurately than conventional assays. Their single-cell multiplexed proteomics platform helps identify the patients most likely to respond to a variety of novel immunotherapies.

Aaron Miller

Aaron Miller
Assistant Clinical Professor
University of California San Diego
Aaron Miller
Assistant Clinical Professor
University of California San Diego
 
About Speaker:

Aaron M. Miller, MD, PhD, is a board-certified medical oncologist who specializes in diagnosing and treating gastrointestinal cancers. This includes cancers of the esophagus, gallbladder, liver, pancreas, stomach, small intestine, bowel and anus. He uses numerous forms of therapy such as chemotherapy, biological therapy, immunotherapy and targeted therapy to offer the best possible treatment options for his patients. Dr. Miller’s approach to care emphasizes personalized medicine/precision oncology, adoptive cellular therapy, next-generation tumor sequencing and tumor immunology. He is part of the gastrointestinal cancer unit at Moores Cancer Center at UC San Diego Health, where he works alongside a multidisciplinary team to provide patients with highly specialized care.

Dr. Miller is an assistant professor in the Department of Medicine, where he instructs medical students, residents and fellows at UC San Diego School of Medicine. He holds a joint faculty appointment at the La Jolla Institute for Allergy and Immunology and is actively involved in cancer research, with the aim of translating his discoveries in the lab into new ways of treating patients. 

Specifically, Dr. Miller’s research focuses on tumor neoantigen identification as targets for novel immunotherapeutics that are both effective and avoid off-tumor toxicities. He and his colleagues have also created a new patient-derived xenograft platform that allows for preclinical testing of investigational chemotherapeutics and immune therapies.

Kevin Murray

Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
 
About Speaker:

Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.

Joost Oppenheim

Joost Oppenheim
Senior Investigator
NIH NCI
Joost Oppenheim
Senior Investigator
NIH NCI
 
About Speaker:

Dr. Oppenheim pioneered the development of cytokine, chemokine and alarmin fields of research. He is currently studying the role of alarmins that activate toll-like receptors, in inducing immunity to cancer. He has been engaged in translational studies aimed at utilizing alarmins as adjuvants in vaccines for use against infectious agents and tumors. He is also investigating means of blocking the immunosuppressive limb of immunity as exerted by T regulatory cells to augment antitumor immunity. Dr. Oppenheim is the Chief of the Laboratory of Molecular Immunoregulation and the Deputy Director of the Cancer and Inflammation Program at the National Cancer Institute which focuses on the effects of inflammation and the immune response on cancer.

Alexander Rakhmilevich

Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
 
About Speaker:

Dr. Rakhmilevich is a distinguished scientist at the University of W isconsin-Madison. He obtained his MD and PhD degrees in Soviet Union. He has been working in the field of cancer immunology since 1985. His current laboratory research involves the develop ment of cancer immunotherapies using activation of macrophages via CD40 ligation

Jamie Reno

Jamie Reno
Investigative Reporter
Healthline Media
Jamie Reno
Investigative Reporter
Healthline Media
 
About Speaker:

Jamie Reno is a modern-day Renaissance man who is motivated by compassion and by looking beyond political, racial, socio-economic and national boundaries to find common ground. Jamie is one of America’s most accomplished investigative reporters. He’s also an acclaimed author, award-winning singer-songwriter-guitarist, and tireless national and global advocate for cancer patients and their families. Jamie is also a relentless supporter of war veterans, and kids. He’s a three-time survivor of stage IV cancer.

Jamie was a national correspondent for 20 years with Newsweek, where he covered 9/11, the wars in Iraq and Afghanistan, veterans, the White House, cancer breakthroughs, China, and more. He’s also edited and written for such publications as the New York Times, Sports Illustrated, International Business Times, Yahoo Finance, Daily Beast, Healthline, People, Entertainment Weekly, Los Angeles Times, USA Today, and his acclaimed news blog The Reno Dispatch. Jamie has won more than 150 writing awards from the Society of Professional Journalists and the Press Club, and is a four-time winner of the Press Club’s top Best of Show award. Jamie is now an investigative reporter for Healthline, America’s second largest health news site with 80 million monthly visitors.

Recognized for his coverage of America’s veterans, Jamie’s reporting has highlighted and improved the lives of our former warriors suffering from Post-Traumatic Stress (PTSD) and other emotional and physical wounds of war. The lead reporter on the groundbreaking Newsweek investigative series on the 9/11 terrorist attacks, Jamie, along with his colleagues, earned the Magazine Award for General Excellence, the highest honor in magazine journalism.

A three-time, 21-year survivor of stage IV non-Hodgkin’s lymphoma, Jamie is one of the world’s most respected and effective advocates for cancer patients and their families. Jamie has partnered on educational and empowering patient-focused projects with such organizations as the Leukemia and Lymphoma Society, Lymphoma Research Foundation, The Children’s Treehouse Foundation, Steps for Living, Greg Wolf Fund, American Cancer Society, Cancer Care, the Asian Heritage Society and Vital Options International.

Jamie is also a gifted author whose book, Hope Begins in the Dark, is the most popular book ever written about lymphoma. An all-new, groundbreaking edition is scheduled for 2018.

Jamie’s new novel, Snowman on the Pitcher’s Mound, which is receiving glowing reviews, tells the poignant story of a 10-year-old boy who loves baseball and whose mother has been diagnosed with cancer. Jamie is publishing the novel as part of his new Pitcher’s Mound Project for children who have a parent with cancer. He is partnering on this initiative with the Children’s Treehouse Foundation, an esteemed nonprofit 501c3 organization based in Ciolorado.

The Treehouse Foundation’s CLIMB Program for kids who have a parent with cancer is already in 77 American cancer hospitals. The goal for Jamie and the Treehouse Foundation with this new initiative is to get these invaluable resources for families into more than 1,000 cancer hospitals in the US and around the world.

In his “other life,” Jamie is a popular singer-songwriter-guitarist who had a major-label record deal and who has performed and recorded his life-affirming songs with such legendary music artists as Peter Frampton, Charlie Daniels, and members of The Eagles, Chicago, The Beach Boys family, Poco, The Allman Brothers, The Doobie Brothers, Little River Band and Steely Dan. He earned a Best Song award from the San Diego Songwriter’s Guild’s Annual Song Contest.

Told when he was diagnosed with cancer that he would live three years, Jamie is an eternal optimist who has dedicated much of his life to urging and inspiring others who are facing adversity to keep fighting and keep smiling. Jamie was named Survivor of the Year by the Greg Wolf Fund, an organization dedicated to funding research in the fight against blood cancers and helping young cancer patients and their families, and won the San Diego Press Club’s special Drew Silvern Award for his journalism about and for cancer patients.

Jamie studied journalism and political science at San Diego State University, and studied marketing and media at Santa Barbara City College, where he was a debate captain and head of the poli-sci club and on the National Honor Roll. Jamie’s goals are to continue facilitating his diverse talents and vast resources to further advocate for and spread positive messages around the world to cancer patients and their families, war veterans and children.

Jamie lives in San Diego with his wife, Gabriela, and their daughter, Mandy.

Jamie Reno

858-397-4950

jreno@san.rr.com (email)

sdsufan2000@gmail.com (email)

10488 Orozco Road

San Diego,  CA  92124

http://therenodispatch.blogspot.com/2016/01/historic-china-cancer-conference-in.html  (national news blog)

http://pitchersmound.org/reviews.html  (new novel for families)

http://www.hopebeginsinthedark.com (global cancer survivors book) 

http://www.jamiereno.com (music site)

http://www.ibtimes.com/reporters/jamie-reno (International Business Times)

http://www.newsweek.com/authors/jamie-reno  (Newsweek) 

http://www.sbcc.edu/prospective/studentbios/jamie.php (college honors)

http://www.thedailybeast.com/contributors/jamie-reno.html (the daily beast) 

https://www.linkedin.com/in/jamie-reno-7bb4b310/ (LinkedIn)

Blythe Sather

Blythe Sather
Associate Director
Juno Therapeutics
Blythe Sather
Associate Director
Juno Therapeutics
 
About Speaker:

Dr. Blythe Sather received her PhD from the University of Washington, Department of Immunology in 2007. For her thesis, she focused on understanding the role of homing receptors on the function of regulatory T cells in the laboratory of Dr. Danial Campbell at the Benaroya Research Institute in Seattle. During her postdoctoral work at Seattle Children’s Research Institute in the laboratory of Dr. David Rawlings, she focused on developing lentiviral gene therapies and lead a team who did ground breaking work using megaTAL nucleases to insert chimeric antigen receptors (CARs) via gene editing-mediated homologous recombination into the CCR5 locus of primary T cells for HIV therapy. In 2014, her desire to bring these types of therapies to the clinic on a larger scale lead her to move to Juno Therapeutics to help develop their research division. Since at Juno, she been instrumental in building their CAR T cell development platform, leading the multiple myeloma CAR T cell program, as well leading the collaboration with Editas medicine to bring CRISPER-mediated gene editing to CAR and TCR T cell products.

Peggy Scherle

Peggy Scherle
Group Vice President of Discovery
Incyte
Peggy Scherle
Group Vice President of Discovery
Incyte
 
About Speaker:

Peggy received her Ph.D. in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH. Prior to joining Incyte in 2002, Peggy held scientific research positions with DuPont Pharmaceuticals Company and Bristol-Myers Squibb. At Incyte, Peggy has been involved in target validation and drug discovery efforts within the therapeutic areas of inflammation and oncology. Her efforts have focused on the identification and preclinical characterization of small molecule inhibitors of key proteins involved in cell signaling and immune cell function.

Steve Siferd

Steve Siferd
Senior Director, Biopharma Business Development
Cancer Genetics, Inc.
Steve Siferd
Senior Director, Biopharma Business Development
Cancer Genetics, Inc.
 
About Speaker:

Steve Siferd is a sales and marketing executive with 20 years of experience in genetics and molecular biology delivering molecular diagnostics services in support of clinical development projects for biopharma and in vitro diagnostic companies.  Throughout his career, Steve has sought to improve human health by leveraging genomics in the clinical development process to achieve better therapies and outcomes. Steve has extensive experience in the application of next generation sequencing technologies in the clinical and diagnostic development process, and is a recognized expert in precision medicine. 

Steffen Walter

Steffen Walter
Chief Scientific Officer
Immatics
Steffen Walter
Chief Scientific Officer
Immatics
 
About Speaker:

Dr Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology. For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities. In 2015, Dr Walter co-founded Immatics US, Inc. in Houston, Texas as a joint venture between Immatics and MD Anderson Cancer Center (MDACC) to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. As CSO, at Immatics US he leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs. Dr Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Brain and Blood. Dr Walter gained his PhD in Immunology from the University of Tuebingen, Germany.

Immunogenicity & Immunotoxicity
DISTINGUISHED SPEAKERS
Gary Bembridge

Gary Bembridge
Senior Director Scientific Affairs
ABZENA
Gary Bembridge
Senior Director Scientific Affairs
ABZENA
 
About Speaker:

Gary has 20+ years' experience working in the biopharmaceutical sector. Since joining Abzena in 2013 Gary has managed business development activities associated with immunological responses to biotherapeutics ensuring that immunogenicity assessment and bespoke immunological studies are tailored to partner’s needs.  Prior to this Gary worked at Envigo as a Biopharmaceutical Product Development Manager and shared responsibility for designing safety studies and non-clinical development programmes for all biologics, providing scientific support and advice to the immunology department. Previous roles at GSK’s included Biology Leader investigating the immunogenicity and efficacy of DNA vaccines, molecular adjuvants and anti-inflammatory antagonist mAbs where he co-authored several patents in these fields.  Gary completed his PhD from the University of Bristol, Department of Veterinary Medicine.

Kei Kishimoto

Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
 
About Speaker:

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines b ased on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provid ed the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto receive d his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Eszter Lazar-Molnar

Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
 
About Speaker:

Dr. Lazar-Molnar is an assistant professor in the Department of Pathology at the University of Utah School of Medicine. She received her PhD in biological sciences at the Semmelweis University in Budapest, Hungary and completed a postdoctoral fellowship in the laboratory of Dr. Stanley G. Nathenson at the Albert Einstein College of Medicine in Bronx, New York, where she was studying immune regulation through costimulatory molecules and finding new ways for designing immunotherapy. She was the recipient of a Cancer Research Institute postdoctoral fellowship and the Belfer Outstanding Postdoctoral Research Award in 2009. She completed a clinical immunology fellowship at the University of Utah and is currently a medical director in Immunology at ARUP and assistant director of the Histocompatibility & Immunogenetics Laboratory at the University of Utah. Her research interests include cellular immunology, immunotherapy, and transplantation immunology. Dr. Lazar-Molnar is board certified by the American Board of Medical Laboratory Immunology (ABMLI) and American Board of Histocompatibility and Immunologenetics (ABHI).

Hong-Gee Lee

Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
 
About Speaker:
Meina Liang

Meina Liang
Director, Clinical Immunology and Bioanalysis
MedImmune
Meina Liang
Director, Clinical Immunology and Bioanalysis
MedImmune
 
About Speaker:

Dr. Meina Liang has broad experiences in drug development of small molecule and biologics across therapeutic areas, including antibody-drug conjugate and immunotherapy. Dr. Liang is currently director of Clinical Immunology and Bioanalysis at Medimmune, a subsidiary of AstraZeneca. She leads a centralized functional group supporting Medimmune portfolio from preclinical to post marketing, responsible for biomarker development for pharmacodynamics and patient stratification, pharmacokinetics bioanalysis for exposure-response evaluation, in vitro cytokine release testing for safety assessment, and immunogenicity assessment for regulatory submission. Her group also contributes to investigation of mechanism of action and lead selection of candidate drugs as well as development of companion diagnostics. Dr. Liang manages a GLP laboratory and also plays a DMPK project leader role for safety studies and clinical trials. She contributes to global regulatory interactions and submissions, including INDs, CTAs, IMPDs and BLAs.

Prior to joining Medimmune, Dr. Liang was a senior scientist at Abgenix, leading a centralized antibody-screening group for lead selection and characterization of therapeutic antibodies. Before Abgenix, Dr. Liang was a scientist at Berlex Biosciences, supporting small molecule drug discovery and development and played a key role in advancing a chemokine project from concept to clinical trials.

Dr. Liang holds B.S in Pharmacy from Peking University Medical School in China and Ph.D in Pharmacology from Univ. of North Carolina at Chapel Hill. She received postdoctoral training from University of Virginia. Dr. Liang is a co-inventor for a number of patents, has published numerous articles in peer-reviewed journals and has been invited to present at many international conferences.

Zuben Sauna

Zuben Sauna
Principal Investigator, Haematology, Research and Review
CBER, FDA
Zuben Sauna
Principal Investigator, Haematology, Research and Review
CBER, FDA
 
About Speaker:

Zuben Sauna is a Principal Investigator and a Reviewer at the US Food and Drug Administration. His research interests lie in understanding the pharmacogenetic basis of the immune response to proteins used in therapeutic interventions as these affect efficacy and safety. His laboratory exploits a combination of computational, in vitro and ex vivo approaches to understand why some individuals and/or sub-populations develop immune responses while others do not. His work has published extensively in high impact journals such as Nature Biotechnology, Nature Medicine, Science, Science Translational Medicine and Nature Reviews Genetics. He received his Ph.D. from Poona University, India with subsequent training at the National Cancer Institute, Bethesda, USA.

David W. Scott

David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
 
About Speaker:

David W. Scott, Ph.D. is Vice Chair for Research, Department of Medicine, Uniformed Services School of Health Sciences, Bethesda, MD. An alumnus of Antioch College, University of Chicago (MS) and Yale (PhD). Following a fellowship at Oxford University, he held tenured positions at Duke University, University of Rochester, and University of Maryland Medical School. Dr. Scott has contributed to over 200 research papers on immunologic tolerance, and its application in autoimmune diseases, hemophilia and gene therapy. The author of two textbooks, including The Nature of Immunologic Tolerance, he ia recipient of a number of awards, e.g. Distinguished Service Award from the American Association of Immunologists, a Boarhaave Professorship at Leiden University in Holland, and the 2009 Scientific Achievement Award from AAPS.

Frances Terry
Frances Terry

EpiVax
 
About Speaker:

Frances Terry is the Director of Analysis at EpiVax, Inc. Ms. Terry obtained her Master of Public Health degree at Brown University in Providence, Rhode Island. At EpiVax, she oversees statistical and bioinformatics-based analysis of wet and dry lab projects focused on immunogenicity prediction for therapeutic proteins and development of genome-derived vaccines.

Albert J Wong

Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
 
About Speaker:

Dr. Wong received his M.D. from the Johns Hopkins School of Medicine. He did a postdoctoral fellowship at the Hopkins Oncology Center under Dr. Bert Vogelstein and then held faculty positions at the Fox Chase Cancer Center and the Thomas Jefferson University before joining the Cancer Biology Program and the Dept. of Neurosurgery at Stanford University in 2005. Focusing on the causes and immunotherapy of human brain tumors, Dr. Wong has made several key discoveries, including the identification of the EGFRvIII alteration and the Gab1 signaling molecule. He showed that EGFRvIII can be used as a vaccine to treat brain tumors, which has led to several clinical trials. This led him to found the biotech company Alteris Therapeutics and as its President led its successful acquisition by Celldex Therapeutics. He has served on numerous review committees for the NIH and ACS, has been an advisor to several universities and pharmaceutical companies, and has been recognized with several honors, including Who’s Who in America, and finalist for regional Biotech Company of the Year.